We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer.
- Authors
Warren, Laura E.G.; Niman, Samuel M.; Remolano, Marie C.; Landry, Jean M.; Nakhlis, Faina; Bellon, Jennifer R.; Aizer, Ayal A.; Lin, Nancy U.; Tolaney, Sara M.; Regan, Meredith M.; Overmoyer, Beth A.; Lynce, Filipa
- Abstract
Background: Patients with inflammatory breast cancer (IBC) have a high risk of central nervous system metastasis (mCNS). The purpose of this study was to quantify the incidence of and identify risk factors for mCNS in patients with IBC. Methods: The authors retrospectively reviewed patients diagnosed with IBC between 1997 and 2019. mCNS‐free survival time was defined as the date from the diagnosis of IBC to the date of diagnosis of mCNS or the date of death, whichever occurred first. A competing risks hazard model was used to evaluate risk factors for mCNS. Results: A total of 531 patients were identified; 372 patients with stage III and 159 patients with de novo stage IV disease. During the study, there were a total of 124 patients who had mCNS. The 1‐, 2‐, and 5‐year incidence of mCNS was 5%, 9%, and 18% in stage III patients (median follow‐up: 5.6 years) and 17%, 30%, and 42% in stage IV patients (1.8 years). Multivariate analysis identified triple‐negative tumor subtype as a significant risk factor for mCNS for stage III patients. For patients diagnosed with metastatic disease, visceral metastasis as first metastatic site, triple‐negative subtype, and younger age at diagnosis of metastases were risk factors for mCNS. Conclusions: Patients with IBC, particularly those with triple‐negative IBC, visceral metastasis, and those at a younger age at diagnosis of metastatic disease, are at significant risk of developing mCNS. Further investigation into prevention of mCNS and whether early detection of mCNS is associated with improved IBC patient outcomes is warranted. Patients with inflammatory breast cancer (IBC), particularly those with triple negative IBC, visceral metastasis, and those at a younger age at diagnosis of metastatic disease, are at significant risk of developing central nervous system metastasis (mCNS). Further investigation into prevention of mCNS and whether early detection of mCNS is associated with improved IBC patient outcomes is warranted.
- Subjects
CENTRAL nervous system; BREAST cancer; NEURAL development; DISEASE risk factors; METASTASIS
- Publication
Cancer (0008543X), 2022, Vol 128, Issue 23, p4085
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.34441